Nienke van Rein

PhD
Leiden University Medical Center, department of Clinical Pharmacy and Toxicology and Clinical Epidemiology
Leiden, Zuid-Holland, Netherlands

Presentation(s):

• PB0420 - Study protocol for the DISTINCT trial: inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hIp or total kNee replaCement.

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0003 - Time trends in vitamin K antagonist (VKA) treatment in the Netherlands in an era of transition to DOACs and lowering of VKA target intensity

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 23.3 - Concurrent use of novel antidiabetic drugs and risks of adverse events among atrial fibrillation patients receiving chronic anticoagulation

  Sunday, June 23, 2024
  15:15 – 15:30 ICT

• OC 23.4 - Long-term maternal risk of cardiovascular diseases after pregnancy in the era of increasing aspirin use for preventing preeclampsia: A nationwide population-based study in the Netherlands

  Sunday, June 23, 2024
  15:30 – 15:45 ICT

• OC 31.5 - Time trends (2013-2019) in antithrombotic therapy prescriptions and thromboembolic complications during the postpartum period in the Netherlands: a nationwide study

  Monday, June 24, 2024
  10:30 – 10:45 ICT

• OC 53.4 - Quantitative targeted proteomics identifies novel biomarkers for prediction of major bleeding during anticoagulation: a prospective case-cohort study.

  Tuesday, June 25, 2024
  10:15 – 10:30 ICT

• PB0989 - Performance of Risk Scores in Predicting Major Bleeding in LVAD Recipients

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1181 - Plasma proteomic profiles of patients during anticoagulant treatment with vitamin K antagonists.

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT